Purpose: This study evaluates the outcomes of ruthenium-106 (Ru-106) plaque brachytherapy for vasoproliferative tumors (VPTs) of the ocular fundus in a single referral ocular oncology center.
Methods: The clinical charts of all patients diagnosed with VPT who underwent plaque radiotherapy from 2002 to 2017 were reviewed. Clinical features, types of treatment, outcomes and complications were evaluated.
Results: Of 46 patients with VPT diagnosis in our ocular oncology clinic, 25 (54.34%) cases were treated with Ru-106 plaque brachytherapy. Eleven patients (44%) were male, and the mean age at the time of diagnosis was 40.92 ± 13.11 years. The mean follow-up time was 47.56 ± 36.87 months. Inferotemporal quadrant was the most common site of the tumor (64.00%). The mean delivered apex and scleral dose was 101.56 ± 6.51 and 412.26 ± 113.66 Gray (Gy), respectively. Initial tumor length, width and thickness were 10.26 ± 3.42, 8.05 ± 2.83 and 4.27 ± 1.10 mm, respectively. The mean tumor thickness decreased to 2.60 ± 0.63 mm, postoperatively. Complete resolution of subretinal fluid around the tumor was achieved in 81.80% of cases. Visual acuity was more than 20/400 in 64% of patients before treatment and 60% of patients at last follow-up.
Conclusion: Our study showed that Ru-106 plaque radiotherapy is an effective and safe method of treatment in VPTs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10792-020-01386-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monte Carlo investigation of dose distribution of two model Ru/Rh ophthalmic plaques in a realistic human eye model with different uveal melanoma size.
Appl Radiat Isot
December 2024
Department of Physics, Faculty of Science, University of Guilan, Rasht, Iran. Electronic address:
Uveal melanoma is the most common primary eye cancer with the highest incidence. BEBIG Ru/Rh ophthalmic plaques more used for the treatment of these eye malignancies, mainly malignancies with small to medium sizes. In this study, we evaluate dose distributions around a voxelized eye phantom due to CCA and CCB eye plaque using GATE code.
View Article and Find Full Text PDFLocal tumour control and patient survival after ruthenium-106 brachytherapy for small choroidal melanoma.
Br J Ophthalmol
December 2024
Ocular Oncology Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
Aim: To report local tumour control, metastasis and survival rates of patients with small choroidal melanoma (CM) after treatment with ruthenium-106 (Ru-106) plaque brachytherapy.
Methods: Retrospective case series of 353 consecutive eyes with small CM (thickness ≤2.5 mm and largest basal diameter ≤16 mm) treated with Ru-106 brachytherapy at the London Ocular Oncology Service, between October 2004 and May 2019.
Monte Carlo-based dosimetry of proposed bi-radionuclide (I and Ru/Rh) eye plaque: A feasibility study.
Med Phys
October 2024
Radiological Physics and Advisory Division, Health, Safety & Environment Group, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Background: Combining the sharp dose fall off feature of beta-emitting Ru/Rh radionuclide with larger penetration depth feature of photon-emittingI radionuclide in a bi-radionuclide plaque, prescribed dose to the tumor apex can be delivered while maintaining the tumor dose uniformity and sparing the organs at risk. The potential advantages of bi-radionuclide plaque could be of interest in context of ocular brachytherapy.
Purpose: The aim of the study is to evaluate the dosimetric advantages of a proposed bi-radionuclide plaque for two different designs, consisting of indigenous I seeds and Ru/Rh plaque, using Monte Carlo technique.
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma.
Brachytherapy
July 2024
Ocular Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; Catholic University "Sacro Cuore", Rome, Italy.
Background: We report a case of personalized exclusive brachytherapy treatment for the management of a highly recurrent squamous cell conjunctival carcinoma with corneal invasion.
Case Description: This is a case of a Caucasian 81-years-old man who presented 10 years ago to our clinic with a pink-white para-limbal mass with dilated feeder arteries and mild leukoplakia. Excisional biopsy confirmed the presence of conjunctival intraepithelial neoplasia (CIN).
Dosimetric Investigation of Six Ru-106 Eye Plaques by EBT3 Radiochromic Films and Monte Carlo Simulation.
J Biomed Phys Eng
August 2023
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Background: Ophthalmic brachytherapy using radioactive plaques is an effective technique for the treatment of uveal melanoma. Ru-106 eye plaques are considered as interesting issue due to their steep gradient dose. The pre-planning evaluation of dosimetric parameters is essential for the treatment planning system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!